iPSC-Derived Human Neurons and Glia from BrainXell

• Direct contact technical support
• Find products for your research

Human Cells of the CNS

Subtype-specific human cells of the central nervous system are invaluable tools for advancing our understanding of various disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), epilepsy, depression, and more. By generating terminally differentiated neurons, astrocytes, and microglia from induced pluripotent stem cells (iPSCs), researchers gain access to a virtually unlimited supply of these highly relevant models. These cells can be derived from both control and disease lines, sourced from publicly available disease banks or created through precise DNA editing. The resulting cells are versatile, supporting traditional 2D cultures or incorporation into complex 3D models, expanding the possibilities for groundbreaking research. We believe model systems employed in biomedical research should have the highest possible relevance to the normal human physiology and disease pathophysiology. Thus, the company was built to provide neurons and glia that can replace the non-human and/or immortalized cell lines traditionally utilized early in drug discovery. We aim to provide cells, medium supplements, and experimental protocols optimized for use single experiments as well in high-throughput screening (HTS).

Technology

BrainXell leverages proprietary technology to refine traditional stem cell differentiation processes, utilizing morphogens to guide stem cells through precise cell fate determination stages that mimic embryonic development. This approach produces cells that closely resemble primary neurons, setting them apart from rapidly differentiated alternatives. Each batch is cryopreserved at a late developmental stage, ensuring convenient shipment and long-term storage in liquid nitrogen. BrainXell’s optimized protocols enable rapid maturation after plating, empowering researchers to effectively study human neuronal functions and pathways in vitro.

Custom offering

BrainXell extends its expertise in control cell production to offer custom services, allowing researchers to generate tailored batches of neurons or glia from novel patient-derived or genetically edited iPSC lines. These custom batches can range from 10 million to over 10 billion cells, providing flexibility to meet diverse research needs. With experience working on hundreds of unique iPSC lines, BrainXell has successfully produced thousands of vials representing a wide variety of disorders, enabling researchers to advance their studies with highly specialized cellular models.

Cells on Demand

BrainXell offers a broad inventory of cell types and vial sizes, with various modifications available, including reporter lines (eGFP, GCaMP, RCaMP) and gene-edited lines (TREM2, APOE, PSEN, APP). Custom batches can be produced quickly, leveraging extensive historical knowledge of successful iPSC lines. Additionally, BrainXell enhances its capabilities through fibroblast reprogramming into iPSCs using advanced mRNA technology, enabling researchers to access cutting-edge tools for their studies.